The first quarter of 2025 has seen a continued rise in Software as a Medical Device (SaMD) submissions, particularly for AI-powered diagnostics, digital monitoring tools, and algorithmic triage systems. Several themes are emerging from FDA and EU clearances that will shape how innovators approach submission strategy for the rest of the year.
First, hybrid evidence strategies are winning. Submissions that blend retrospective real-world data with small-scale prospective validation studies are being accepted more frequently. Regulators appear to favor practicality over perfection—provided the clinical rationale is well-defended.
Second, labeling is evolving. Successful submissions are using patient-centric claims, focusing on “supporting” rather than “replacing” clinician judgment. This positioning lowers regulatory risk and aligns with ethical use of AI.
Third, modular documentation is gaining ground. The use of dynamic model updates (MLU) within a pre-specified change control plan is no longer novel—it’s expected. Teams that submit clear protocols for ongoing learning and post-market model governance stand out.
The takeaway? SaMD in 2025 isn’t just about model performance—it’s about clarity, humility, and systems thinking. If your submission reads like a complete product lifecycle plan rather than a static artifact, you’re on the right track.